You’ve built something real. An AI product — maybe a predictive model, a diagnostic algorithm, a generative tool, or a proprietary dataset that powers something nobody else has. You’ve got traction. You might be fundraising. And somewhere in the back of your mind, you know your technology is what makes this whole thing valuable.
Here’s the question most AI founders don’t ask until it’s too late: do you actually own it?
Not “did we register it” or “did we file a patent.” I mean: have you thought through all four layers of IP in an AI product — who created what, under what agreement, trained on what data, and whose name is on what — in a way that would hold up under investor due diligence or a licensing negotiation?
I’ve spent 35 years in IP licensing across entertainment, consumer products, MedTech, and digital markets. I’ve watched deals collapse because of IP ownership questions nobody asked when the company was young and moving fast. AI startups are walking into this problem at scale right now. The good news: it’s completely fixable if you catch it early.
This is your guide to understanding what you actually own, what you might not, and how to turn your AI IP into a real commercial asset through licensing.
Not sure if you actually own your AI IP? Let’s find out together. Schedule a Free 15-Minute Strategy Call →
Why AI IP Is Different — and Why It Matters More Than Ever
Most startup founders understand IP in general terms: file a patent, protect your brand, make sure employees sign assignment agreements. That framework still applies. But AI products have four distinct IP layers that traditional products don’t — and most founders are only thinking about one or two of them.
Here’s the full picture:
- Layer 1 — The training data
- Layer 2 — The model architecture
- Layer 3 — The trained model weights
- Layer 4 — The outputs and applications
Each layer can be owned, licensed, or disputed separately. And in 2026, with AI deal activity at an all-time high — the FDA has authorized more than 1,200 AI-enabled medical devices, pharma companies like MSD are signing multi-billion-dollar AI licensing agreements, and investors are paying serious premiums for companies with defensible AI IP — the stakes of getting this wrong have never been higher.
Let me walk through each layer.
Layer 1 — Your Training Data: The Most Overlooked IP Risk
Your model is only as valuable as what it was trained on. And if that training data belongs to someone else — which it often does — you have a problem.
The most common issues founders run into:
- Scraped public data that has terms of service prohibiting commercial use
- Licensed datasets where the license covers internal research but not commercial products
- Third-party content (text, images, audio, code) where the copyright holder never gave permission for AI training
- Customer data used to fine-tune models where the customer agreement is ambiguous about who owns the resulting improvements
This isn’t hypothetical. Getty Images, The New York Times, and dozens of other rights holders have filed or pursued litigation specifically around AI training data. The legal landscape is still developing, but the risk is real and growing.
For founders: before you can confidently license your AI technology to a corporate partner or raise a Series A with clean IP, you need to know exactly what your model was trained on — and whether your right to use that data extends to commercial licensing. If it doesn’t, the solution isn’t to panic. It’s to document the risk, develop a remediation plan, and get that into your IP strategy now.
What to do: Conduct a training data audit. Identify every dataset used, map the license terms for each, and flag anything that doesn’t clearly permit commercial use. This is one of the first things sophisticated acquirers and enterprise licensees will ask for.
Layer 2 — Your Model Architecture: What’s Actually Patentable
This is where most AI founders either over-invest or under-invest. They either try to patent everything (including things that aren’t patentable) or assume nothing is patentable and skip it entirely.
In November 2025, the USPTO issued revised guidance on AI inventorship that settled a question founders have been asking for two years: only natural persons can be inventors on a patent application, even when AI played a significant role in the creative process. The USPTO is explicit — AI is treated like laboratory equipment or software. It assists. It does not invent.
What that means practically: if a human engineer at your company made the meaningful conceptual contribution to your model architecture, that work is patentable. The AI tools they used to get there don’t change that. The key is being able to document the human contribution clearly — who conceived of the specific technical solution, and when.
What is and isn’t patentable in AI:
- ✅ Novel model architectures that solve a specific technical problem
- ✅ Specialized training methods or data preprocessing pipelines that are non-obvious
- ✅ AI-powered systems where the innovation is in the system design, not just the output
- ✅ Hardware-software combinations that implement AI in a novel way
- ❌ Abstract mathematical algorithms without more
- ❌ “Using AI to do X” where the AI component is generic
- ❌ The outputs of the model themselves — images, text, generated code
For founders who aren’t sure where their architecture lands, ask yourself this: could a competitor build something that performs similarly without using your specific technical approach? If yes, your moat is thin. If no — if your approach is genuinely novel and non-obvious — that’s where patent protection creates real licensing leverage.
Layer 3 — Your Trained Model Weights: Trade Secret or Patent?
This is the layer most founders don’t think about at all. And it’s often where the most valuable IP actually lives.
Once you’ve trained a model, the resulting weights — the billions of learned parameters that define how your model behaves — are a distinct asset from the architecture that produced them. They represent enormous invested value: compute costs, data curation time, engineering effort. And they’re often what makes your specific implementation outperform everything else on the market.
Trade secret protection is usually the right strategy here. Unlike a patent, a trade secret never expires, doesn’t require public disclosure, and protects something that’s genuinely hard to reverse-engineer. Companies like OpenAI, Google DeepMind, and Anthropic treat their model weights as some of their most carefully guarded assets — not because they can’t patent them, but because trade secret protection is stronger in this context.
The practical requirements for trade secret protection are straightforward: you have to treat the weights like a secret. Access controls, employee NDAs, contractor agreements that clearly assign ownership, and documented internal procedures that show you took the secrecy seriously.
A real example from our advisory work: A digital health startup had built a predictive model for patient triage that significantly outperformed available alternatives. They were about to sign a licensing deal with a hospital network — their first significant commercial agreement. During our IP review, we found that three contractors who had contributed to the model weights had never signed IP assignment agreements. The hospital’s legal team flagged it immediately. We spent six weeks cleaning it up before the deal could close — six weeks of revenue delayed and legal costs incurred because of paperwork that should have been done in week one.
What to do: Audit every person who touched your model weights — employees, contractors, research collaborators, academic partners. Make sure every one of them has a signed IP assignment agreement covering their specific contribution. Then implement trade secret controls as if a competitor could subpoena your Slack history tomorrow. Because they might.
📘 Want the full picture on what’s driving IP licensing deals in 2026? Download the free eBook: IP Licensing Trends 2026 Get Your Free Copy →
Layer 4 — Your Applications and Outputs: Where the Licensing Revenue Lives
Here’s the layer that most directly connects to revenue: what your AI actually produces, and who can use it for what.
Even if you can’t patent the underlying model, you can absolutely license the application — the specific use of your AI in a defined industry, geography, or context. That’s a business arrangement, not a patent requirement, and it can generate significant recurring royalty income.
Consider how this works at scale. Qualcomm doesn’t manufacture most of the chips that run on its technology — it licenses the IP. ARM Holdings, whose processor designs power virtually every smartphone on earth, generates billions in annual royalty revenue by licensing architecture to chipmakers rather than building chips itself.
You don’t need to be ARM to apply this model. An AI startup with a proprietary diagnostic algorithm can license its use in radiology to one company, in pathology to another, and in insurance underwriting to a third — each as a separate agreement with separate royalty streams. The IP stays yours. The applications go to whoever is best positioned to commercialize them in each market.
For early-stage AI founders, the most relevant licensing structures include:
- Exclusive regional licenses — one company gets rights in a defined geography
- Field-of-use licenses — one company gets rights in a specific industry vertical
- White-label agreements — another company deploys your AI under their brand
- API licensing — companies access your model’s capabilities via a structured interface
- Embedded technology licenses — your AI becomes a component in someone else’s product
Each of these generates royalty income without requiring you to scale your own operations, hire a sales team, or build out customer success. It’s revenue that grows with your licensee’s success.
The Four Questions Every AI Founder Should Answer Right Now
Before your next investor meeting, enterprise pilot, or term sheet negotiation, you should be able to answer these four questions clearly:
1. Do we have documented proof that our employees and contractors assigned all AI-related IP to the company?
2. Do we know exactly what data our model was trained on, and can we confirm our commercial right to use it?
3. Have we identified which elements of our architecture or application are patentable — and made a deliberate decision about whether to pursue patents?
4. Have we implemented trade secret controls on our model weights?
If the answer to any of these is “I’m not sure” or “mostly,” that’s not a crisis. But it is work that needs to happen before it becomes one.
Turning Your AI IP Into a Revenue Stream
The most important mindset shift for AI founders who want to build real IP value isn’t about protection. It’s about monetization. Protection is table stakes. Monetization is strategy.
The companies that get the most value out of their AI IP aren’t necessarily the ones with the most patents. They’re the ones who’ve thought carefully about what they have, who would pay to use it, and how to structure deals that generate recurring income without giving away control.
That’s exactly the conversation we have on strategy calls at LCG. We work with IP owners — including AI founders looking to understand and commercialize their technology — to map what’s licensable, identify the right target companies, and structure deals that work.
If you’re building an AI product and you want to make sure you own what you think you own — and know how to turn it into revenue — let’s talk.
Ready to talk about your AI IP?
Schedule a free 15-minute strategy call with Rand Brenner. We’ll look at your specific situation — what you have, what it’s worth, and the best path to a deal.
Stay in the Loop: The LCG Newsletter
Get Rand Brenner’s weekly insights on IP licensing strategy, deal structures, and market intelligence — written for IP owners and founders who want to turn their innovations into income. No fluff. Just what works.
Subscribe to the LCG Newsletter →
Rand Brenner is an IP professional whose passion is helping inventors, startups, and businesses use licensing to turn their IP into income-producing products, services, and technologies. His decades of experience run the gamut from medical devices to food technology to consumer products. He’s licensed some of the biggest Hollywood entertainment blockbusters, including the Batman Movies (1 and 2) and the number one kid’s action TV show, the Mighty Morphin Power Rangers. Rand speaks about licensing and is a featured speaker at investment conferences, trade shows, colleges, and startup events. His first book, Hidden Wealth: The Money-Making Power of Licensing, was released in 2019 and is available on Amazon.com. He’s also a published writer, and his articles have appeared in several prestigious trade magazines, including The Licensing Journal, Intellectual Property Magazine, and License India.
Working Through a Licensing or Commercialization Challenge?
If you have market-ready intellectual property, a licensing campaign that has stalled, or a business opportunity that may benefit from licensing, a short strategy discussion can help clarify the next step.